Literature DB >> 12592386

Overexpression of Cdk6-cyclin D3 highly sensitizes cells to physical and chemical transformation.

Qiuhong Chen1, Jie Lin, Shigeki Jinno, Hiroto Okayama.   

Abstract

Virtually all mammalian cells express two seemingly redundant cyclin-D-dependent kinases (Cdk4 and Cdk6) and three partner cyclins (D1, D2 and D3) essential for the G(1)-S transition, with predominant expression of Cdk4 and D1 in mesenchymal cells and Cdk6 and D3 in hematopoietic cells. We recently found two novel functions for Cdk6 executed in fibroblasts although unlike Cdk4 it is dispensable for their proliferation. In the rat fibroblast NRK-49F cells, oncogenic stimulation recruits Cdk6 to participate in a step of the cell cycle start that seems to be critical for anchorage-independent S-phase onset. Among the kinase-D-type cyclin combinations, the Cdk6-cyclin-D3 complex has a unique ability to evade inhibition by cyclin-dependent kinase inhibitors and thereby control the cell's proliferative competence under growth-suppressive conditions. We describe here that 2-5-fold overexpression of both Cdk6 and D3 enhances by 5x10(3)-10(6)-fold the susceptibility of the BALB/c3T3 and C3H10T1/2 mouse fibroblast lines to ultraviolet irradiation- as well as 3-methylcholanthrene-induced transformation. This result suggests that deregulated expression of Cdk6 and cyclinD3 may predispose cells to malignant transformation, supporting the recent finding that cyclin D3 activated by chromosomal rearrangement is the causative gene of non-Hodgkin B lymphoma, in which Cdk6 is the major partner kinase.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12592386     DOI: 10.1038/sj.onc.1206193

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  7 in total

1.  Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer.

Authors:  Gottfried E Konecny; Boris Winterhoff; Teodora Kolarova; Jingwei Qi; Kanthinh Manivong; Judy Dering; Guorong Yang; Meenal Chalukya; He-Jing Wang; Lee Anderson; Kimberly R Kalli; Richard S Finn; Charles Ginther; Siân Jones; Victor E Velculescu; Darren Riehle; William A Cliby; Sophia Randolph; Maria Koehler; Lynn C Hartmann; Dennis J Slamon
Journal:  Clin Cancer Res       Date:  2011-01-28       Impact factor: 12.531

2.  G1/S transcriptional networks modulated by the HOX11/TLX1 oncogene of T-cell acute lymphoblastic leukemia.

Authors:  Irene Riz; Robert G Hawley
Journal:  Oncogene       Date:  2005-08-25       Impact factor: 9.867

3.  Bone morphogenetic protein 2-induced osteoblast differentiation requires Smad-mediated down-regulation of Cdk6.

Authors:  Toru Ogasawara; Hiroshi Kawaguchi; Shigeki Jinno; Kazuto Hoshi; Keiji Itaka; Tsuyoshi Takato; Kozo Nakamura; Hiroto Okayama
Journal:  Mol Cell Biol       Date:  2004-08       Impact factor: 4.272

4.  Inhibition of mTOR restores cisplatin sensitivity through down-regulation of growth and anti-apoptotic proteins.

Authors:  Medhi Wangpaichitr; Chunjing Wu; Min You; M T Kuo; Lynn Feun; Theodore Lampidis; Niramol Savaraj
Journal:  Eur J Pharmacol       Date:  2008-06-12       Impact factor: 4.432

5.  Glabridin arrests cell cycle and inhibits proliferation of hepatocellular carcinoma by suppressing braf/MEK signaling pathway.

Authors:  Ziyou Wang; Shengqun Luo; Zheng Wan; Chuyan Chen; Xiangning Zhang; Binbin Li; GuoLiang Huang; Liyong Chen; Zhiwei He; Zunnan Huang
Journal:  Tumour Biol       Date:  2015-11-19

6.  Licochalcone B Ameliorates Liver Cancer via Targeting of Apoptotic Genes, DNA Repair Systems, and Cell Cycle Control.

Authors:  Kadry Sadek; Tarek Abouzed; Sherif Nasr; Moustafa Shoukry
Journal:  Iran J Pharm Res       Date:  2020       Impact factor: 1.696

7.  Spontaneous genomic alterations in a chimeric model of colorectal cancer enable metastasis and guide effective combinatorial therapy.

Authors:  Yinghui Zhou; William M Rideout; Angela Bressel; Sireesha Yalavarthi; Tong Zi; Darren Potz; Samuel Farlow; Joelle Brodeur; Anthony Monti; Shailaja Reddipalli; Qiurong Xiao; Steve Bottega; Bin Feng; M Isabel Chiu; Marcus Bosenberg; Joerg Heyer
Journal:  PLoS One       Date:  2014-08-27       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.